Navigation Links
Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma
Date:1/7/2009

ipants in the solicitation of proxies from the stockholders of Nuvelo in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction is included in the proxy statement/prospectus/consent solicitation described above. Additional information regarding the directors and executive officers of Nuvelo is also included in Nuvelo's proxy statement for its 2008 Annual Meeting of Stockholders which was filed with the SEC on April 23, 2008 and its Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the SEC on March 12, 2008. These documents are available as described above.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. Nuvelo Reports Second Quarter 2008 Financial Results
3. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
4. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
5. Nuvelo and ARCA biopharma Advance Toward Completion of Merger
6. Nuvelo Announces Positive Results from Phase 1 Clinical Trial of NU206 in Healthy Volunteers
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
9. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
10. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
11. Pharmos Issues Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Stem cells battle for space 2How to read brain activity? 2MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 1MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 2MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 3MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 4MEDA Receives FDA Approval of New ASTEPRO 28R 29 28azelastine HCl 29 Nasal Spray 0 15 25 the First and Only Once Daily Nasal Antihistamine 55998 5Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 55994 1Providence Service Corporation to Present at the Baird 2009 Healthcare Conference on September 9 55994 2Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 1Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 2Derma Sciences To Present at Rodman 26 Renshaws Eleventh Annual Healthcare Conference 55990 3